Gabriela Hobbs: Emerging Myelofibrosis Therapies at EHA 2026
Gabriela Hobbs, Leukemia Clinical Director at Massachusetts General Hospital, Associate Professor at Harvard Medical School, shared Priya Sriskandarajah’s post on LinkedIn:
“Thankful for the opportunity to discuss emerging therapies in Myelofibrosis at this year’s EHA in lovely Sweden with Stefan Schleding, Gonzalo Carreño and Steffen Koschmieder.”
Priya Sriskandarajah, Consultant Haematologist at Guy’s and St Thomas’ NHS Foundation Trust, shared a post on LinkedIn:
“Next session covering management of cytopenic myelofibrosis – a very challenging cohort but some exciting new therapies coming especially combination options.
Excellent presentations by Stefan Scheding, Gonzalo Carreno and Gabriela Hobbs with chair Steffen Koschmieder.”
Stay updated with Hemostasis Today.
-
Aug 6, 2026, 04:58Shamee Shastry: Advancing Precision in Massive Bleed Management
-
Aug 6, 2026, 01:21Orly Leiva: High-Output Heart Failure Signals Disease Progression in PV and ET
-
Aug 5, 2026, 23:46Recommended ESC Congress Sessions for the ESC Working Group on Thrombosis
-
Aug 5, 2026, 23:36Heghine Khachatryan: ISTH Day 2 – Phase III VAYHIT2 Data Highlights Ianalumab in Primary ITP
-
Aug 5, 2026, 23:28Basyouni Omran: KDIGO 2025/2026 Bedside Guide – Iron Correction in CKD
-
Aug 5, 2026, 23:13C. Michael Gibson: Jean Connors on Antithrombotic Therapy for LVAD at Baim Grand Rounds
-
Aug 5, 2026, 23:07Building Safer Systems for Bleeding and Clotting Care with Dr. Toyosi Onwuemene
-
Aug 5, 2026, 21:19Vidhi Shukla: Anticoagulant Activity of Ficus Racemosa Bark Extract in Rats
-
Aug 5, 2026, 20:30Denis Oduor: Patient Blood Management and Systemic Transfusion Reform